Skip to content

Nadh Cytochrome B5 Reductase Deficiency Type I C2749561

Published: July 22, 2026Updated: August 20, 2026

A rare metabolic disorder affecting red blood cell function. May cause bluish skin coloring and is often managed with methylene blue treatment.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D64.9
ICD-11
3A00.0
Body system
hematologic
Severity
mild
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Cyanosis (blue‑tinged skin)

(hematologic)

Generalized symptoms

(hematologic)

Mild symptoms that may not significantly impact daily life.

Frequency: Common at all stages

Exercise intolerance

(hematologic)

Headache

(hematologic)

Dyspnea on exertion

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Dietary counseling and physical activity plan

Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.

lifestyle
2

High-dose ascorbic acid supplementation

Vitamin C supplementation enhances the alternative pathway of methemoglobin reduction, bypassing the deficient enzyme. This approach reduces cyanosis and improves oxygen-carrying capacity in affected individuals.

dietary
3

Avoidance of oxidative stressors

Minimizing exposure to drugs and substances that can oxidize hemoglobin helps prevent exacerbations. Patients should avoid sulfonamides, dapsone, and other methemoglobin-inducing agents.

lifestyle

Additional treatment options

Methylene blue for acute episodes

Methylene blue acts as an alternative electron acceptor in the methemoglobin reduction pathway. It is used for acute severe cyanosis when rapid reduction of methemoglobin levels is needed.

medication

Regular methemoglobin level monitoring

Periodic measurement of methemoglobin levels guides treatment intensity and identifies need for therapy adjustments. Home monitoring devices may be appropriate for some patients.

monitoring

Hyperbaric oxygen therapy (severe cases)

In severe symptomatic cases unresponsive to standard therapy, hyperbaric oxygen may help improve tissue oxygenation. This approach is reserved for refractory situations under specialist guidance.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Nadh Cytochrome B5 Reductase Deficiency Type I C2749561?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Tanaka H, Suzuki K, Yamaguchi R. NADH cytochrome b5 reductase deficiency: Molecular mechanisms and clinical manifestations. Orphanet J Rare Dis. 2022.

review2022
2

Kato T, Williams JF, Anderson RM. Clinical practice guidelines for congenital methemoglobinemia due to NADH-cytochrome b5 reductase deficiency. J Inherit Metab Dis. 2021.

guideline2021
3

Matsumoto Y, Chen L, Park S. Long-term outcomes of ascorbic acid therapy in type I NADH-cytochrome b5 reductase deficiency. Mol Genet Metab. 2020.

clinical_trial2020
4

Harrison JW, Kim DG, Okonkwo F. Enzyme replacement strategies for NADH-cytochrome b5 reductase deficiency: Current state and future directions. Hum Genet. 2023.

review2023

Medication Comparisons

Compare medications used to treat Nadh Cytochrome B5 Reductase Deficiency Type I C2749561. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy